CervoMed (CRVO) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed CervoMed (CRVO) over the past year, losing 32.1% versus a loss of 63.1%. Over five years, SCYX leads with a -90.5% price change compared with -90.9% for CRVO. CervoMed is the larger company by market cap ($48.7 million vs $40.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | SCYX |
|---|---|---|
| Share price | $3.22 | $4.08 |
| Market cap | $48.68M | $40.59M |
| 1-day change | -1.83% | -3.32% |
| YTD return | -58.48% | -16.53% |
| 1-year return | -63.15% | -32.11% |
| 5-year return | -90.89% | -90.53% |
| EPS (TTM) | $-3.21 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.00 | $9.12 |
| 52-week low | $2.13 | $3.53 |
| Distance from 52-week high | -67.80% | -55.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +378.26% | +790.44% |
| Average volume | 339.08K | 279.10K |
| Shares outstanding | 15.12M | 9.95M |
| Employees | 15 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed CRVO by 31.0 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
CRVO vs SCYX FAQ
Which is bigger, CervoMed or SCYNEXIS?
CervoMed (CRVO) is larger, with a market capitalization of $48.68M compared with $40.59M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, CRVO or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -63.15% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.